Web Date: November 1, 2006
Merck Is To Acquire Sirna
Looking to stay on the cutting edge of drug discovery, Merck & Co. has agreed to shell out $1.1 billion for Sirna Therapeutics, a San Francisco-based biotech firm focused on drugs based on RNA interference.
Merck says Sirna's RNAi technology complements internal efforts on RNA expression that have been under way since its 2001 acquisition of Rosetta Inpharmatics. The company believes the technology combination could significantly change the way drugs are discovered and . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society